DMAC vs GRMN · $157.4M cap vs P/E 28, rev $6.30B
DiaMedica Therapeutics Inc (DMAC) versus Garmin Ltd (GRMN) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Garmin Ltd (GRMN) is a scientific & technical instruments company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported GRMN revenue for 2024-12-28 was $6.30B. Net income was $1.41B. Revenue was up 20.4% from 2023-12-30 to 2024-12-28. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
DMAC currently screens at market cap $157.4M. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
Not investment advice. Open the DMAC and GRMN stock pages for the full models.
Not investment advice.